Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Sunday reports from the 50th annual meeting of the American Society of Clinical Oncology focused on using aromatase inhibitors in premenopausal women with early-stage, estrogen-positive breast cancer and on a negative study of lapatinib for HER2-positive early-stage disease.
Researchers announced findings from breast cancer studies during Saturday’s sessions of the 50th Annual Meeting of the American Society of Clinical Oncology, in Chicago. Today's reports focus on obesity and risk of recurrence in pre- and peri-menopausal women; preserving fertility in young women taking chemotherapy; and the future of bevacizumab (Avastin) in breast cancer.
Breast cancers with a low level of estrogen receptor positivity – only 1 to 9 percent of tumor cells being positive – is more similar to ER-negative disease than to breast cancer with ER positivity of 10 percent or greater, according to a recent study.
African-American women were more likely to stop working during the first 2 months of breast cancer treatment compared with non-Hispanic white peers, an analysis found. The study, published in Journal of Cancer Survivorship, assessed racial differences in quality of life and employment after breast cancer diagnosis.
Having very young children may affect whether women receive radiation therapy after breast-conserving surgery.
The American Society of Clinical Oncology published updates to their 2005 guidelines for use of sentinel lymph node biopsy in early-stage breast cancer. The guidelines, based on the review of 9 randomized clinical trials and 13 cohort studies, reflect what ASCO believes are best practices in using the biopsy.
Trust in medical care received, age, and positive attitude are factors that may affect risk for anxiety or depression among black women newly diagnosed with breast cancer, researchers found.
Everolimus (Afinitor) and exemestane (Aromasin) taken at the same time may be an effective first-line treatment for hormone receptor-positive breast cancer that spread beyond the breast to other organs, after treatment with another aromatase inhibitor. This finding comes from a new analysis of data from the BOLERO-2 trial.
Reconstruction of the breasts after their surgical removal to treat breast cancer may improve body image and sexual satisfaction among women, a study published in Psycho-Oncology suggests. Women who had implant-based or deep inferior epigastric artery perforator (DIEP) flap reconstruction experienced great improvement in these areas in the months following either surgery.
Research presented at the 2014 American Association for Cancer Research Annual Meeting suggests a new treatment pair may help double the time before estrogen receptor-positive, metastatic breast cancer grows or spreads.